Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
8/3/22	G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
8/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/1/22	G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
7/25/22	G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
7/20/22	G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
7/13/22	COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
7/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/28/22	G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
6/13/22	G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
6/2/22	Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy